Lifeloc Technologies, Inc (LCTC): Results of Operations and Financial Condition
Lifeloc Technologies, Inc (LCTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1 Lifeloc Reports Second Quarter 2026 Results WHEAT RIDGE, Colo., August 13, 2026 -- Lifeloc Technologies, Inc. (OTCID: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announc
How this was made
The 30-second read
Why it matters
Traders can update expectations for near-term profitability (continued net losses) and medium-term product execution (SpinDetect beta testing and targeted limited commercial launch in Q1 2027).
Market read
The filing provides fresh quarterly financial datapoints (revenue, net loss, gross margin) and a concrete product timeline that can drive speculative positioning in an OTC name.
What to watch
SpinDetect beta and Q1 2027 limited launch are key catalysts, but the filing does not quantify commercialization traction, cash runway, or dilution risk beyond the $500K loan terms.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 covering Lifeloc’s Q2 2026 operating results, product commentary, and a financing update.
Ticker impact
Lifeloc reports Q2 2026 results with $2.445M revenue, a $134K net loss, and higher gross margin to 45% from 42% a year ago.
Likely modest, two-sided reaction: margin/revenue improvement is supportive, but loss level and financing terms may cap upside.
The filing provides concrete quarterly financials and margin improvement, plus a financing update and a timeline for SpinDetect beta and limited launch in Q1 2027.
Market effects
Breath alcohol and drug testing device makers may see read-across interest in drug-analyzer platform progress and gross margin trajectory.
No clear regional macro linkage beyond a US-based OTC issuer.
Limited global relevance; story is company-specific with product and beta-testing milestones.
Counterpoint
Gross margin improvement may be partly mix/price-driven, while the company still burns cash and relies on asset-secured related-party financing.
Key entities
- issuerLifeloc Technologies, Inc.
OTC-listed developer and manufacturer of breath alcohol and drug testing devices; reports Q2 2026 financials and SpinDetect progress.
- product_platformSpinDetect™ Centrifugal Drug Analyzer
Oral-fluid drug analyzer platform; beta testing targeted for delta-9-THC and limited commercial launch targeted for Q1 2027.
- financingChairman/CFO loan
$500,000 loan closed during the quarter, 10.5% interest with adjustable upward, interest-only in 2026, fully paid in 5 years, secured by all assets.